164 related articles for article (PubMed ID: 22134100)
21. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
Newland MR; Weinstein A; Kerdel F
Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
[TBL] [Abstract][Full Text] [Related]
22. Ustekinumab: when everything else fails?
Vitiello M; Grant A; Kerdel FA
Int J Dermatol; 2011 Apr; 50(4):478-82. PubMed ID: 21413963
[No Abstract] [Full Text] [Related]
23. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
Lisby S; Gniadecki R
Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
[No Abstract] [Full Text] [Related]
24. Body weight increment in patients treated with infliximab for plaque psoriasis.
Florin V; Cottencin AC; Delaporte E; Staumont-Sallé D
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e186-90. PubMed ID: 22621415
[TBL] [Abstract][Full Text] [Related]
25. [Neurological symptoms following infusion of infliximab].
Bebe AC; Harboe KM; Nøjgaard C
Ugeskr Laeger; 2012 Oct; 174(40):2388-90. PubMed ID: 23031302
[TBL] [Abstract][Full Text] [Related]
26. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
[TBL] [Abstract][Full Text] [Related]
27. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients.
Fabroni C; Gori A; Troiano M; Prignano F; Lotti T
J Eur Acad Dermatol Venereol; 2011 May; 25(5):549-53. PubMed ID: 20707829
[TBL] [Abstract][Full Text] [Related]
28. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
Wozel G; Vitéz L; Meurer M
Acta Dermatovenerol Alp Pannonica Adriat; 2008 Sep; 17(3):133-6. PubMed ID: 18853077
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of severe psoriasis with anti-TNF-alpha-antibody and methotrexate].
Dalaker M; Bonesrønning JH
Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1070-1. PubMed ID: 12760225
[No Abstract] [Full Text] [Related]
30. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
31. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.
Hoffmann JH; Hartmann M; Enk AH; Hadaschik EN
Br J Dermatol; 2011 Dec; 165(6):1355-8. PubMed ID: 21801160
[TBL] [Abstract][Full Text] [Related]
32. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
33. [Our experience with infliximab in reclacitrant cases of psoriasis].
Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
[TBL] [Abstract][Full Text] [Related]
34. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
Bartke U; Venten I; Kreuter A; Gubbay S; Altmeyer P; Brockmeyer NH
Br J Dermatol; 2004 Apr; 150(4):784-6. PubMed ID: 15099388
[No Abstract] [Full Text] [Related]
35. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
36. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
37. Topical tazarotene vs. coal tar in stable plaque psoriasis.
Kumar U; Kaur I; Dogra S; De D; Kumar B
Clin Exp Dermatol; 2010 Jul; 35(5):482-6. PubMed ID: 19874376
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
39. Infliximab and nephrotic syndrome.
Chin G; Luxton G; Harvey JM
Nephrol Dial Transplant; 2005 Dec; 20(12):2824-6. PubMed ID: 16204273
[TBL] [Abstract][Full Text] [Related]
40. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study.
Sigurgeirsson B; Kircik L; Nemoto O; Mikazans I; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1127-9. PubMed ID: 24330415
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
